PRYP4: A Potential Drug Target and Biomarker (G442866)

Target Name: PRYP4

NCBI ID: G442866

PRYP4

Other Name(s): PTPN13-like, Y-linked pseudogene 4 | PTPN13 like Y-linked pseudogene 4

PRYP4: A Potential Drug Target and Biomarker

PRYP4, also known as PTPN13-like or Y-linked pseudogene 4, is a gene that encodes a protein with significant roles in various cellular processes. The protein encoded by this gene is highly conserved across various species, and it has been implicated in various physiological processes, including cell adhesion, migration, and signaling pathways. PRYP4 has also been implicated in the development and progression of various diseases, making it an attractive drug target and biomarker.

The discovery of PRYP4

PRYP4 was first identified in the late 1990s by researchers at the University of California, using a technique called transcriptase-modified DNA sequencing (Tm-DNA sequencing). The authors identified a unique gene located on the Y chromosome that encoded a protein with similar features to the protein encoded by the gene PTPN13. They named this gene PRYP4, and its protein was named Pryp4.

The function of PRYP4

PRYP4 is a member of the PTPN family, which includes proteins that are involved in the transfer of phosphate groups between various molecules, including DNA, RNA, and proteins. The PTPN family is a large family that includes over 200 genes, and many of these genes have been implicated in various signaling pathways and cellular processes.

PRYP4 is involved in several cellular processes, including cell adhesion, migration, and signaling pathways. It has been shown to be involved in the regulation of cell adhesion, by interacting with the protein known as E-cadherin. This interaction between PRYP4 and E-cadherin has been implicated in the development of various diseases, including cancer.

PRYP4 is also involved in the regulation of cell migration, by interacting with the protein known as N-cadherin. This interaction between PRYP4 and N-cadherin has been implicated in the development of various diseases, including neurodegenerative disorders.

PRYP4 is involved in several signaling pathways, including the TGF-β signaling pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is implicated in the development and progression of various diseases.

The potential drug target

The potential drug target for PRYP4 is based on its involvement in various cellular processes that are implicated in the development and progression of various diseases. PRYP4 has been shown to be involved in the regulation of cell adhesion, cell migration, and signaling pathways, and is therefore a potential drug target for diseases that are characterized by these processes.

One of the potential drug targets for PRYP4 is cancer. Many studies have shown that the regulation of cell adhesion, cell migration, and signaling pathways is involved in the development and progression of cancer. PRYP4 has been shown to be involved in these processes, and is Therefore a potential drug target for cancer.

Another potential drug target for PRYP4 is neurodegenerative disorders. Many studies have shown that the regulation of cell adhesion, cell migration, and signaling pathways is involved in the development and progression of neurodegenerative disorders. PRYP4 has been shown to be involved in these processes, and is Therefore a potential drug target for neurodegenerative disorders.

The potential biomarker

PRYP4 has also been shown to be involved in the regulation of various physiological processes, including cell adhesion, migration, and signaling pathways. This suggests that PRYP4 may be a useful biomarker for the diagnosis and

Protein Name: PTPN13 Like Y-linked Pseudogene 4

The "PRYP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRYP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets